The Consortium is growing! As of June 2017, there are over 70 people registered on the mailing list representing approximately 51 companies. Please continue to introduce new members and/or companies that may be interested and make suggestions for ideas and events for the AABC to better serve its membership. For future issues of this Newsletter please contact April Ross, aqross@alz.org with the information you would like to include.

For those of you not familiar with the AABC, we encourage you to get involved in 2017/2018 by attending one of our events. Please email Charles Stacey (cstacey@accerapharma.com), Kira Sheinerman (ksheinerman@diamirbio.com) or Jim Hendrix (j hendrix@alz.org) to be added to the membership list mailing list.

Mission of the AABC

The mission of the AABC is to advance Alzheimer’s disease research and innovation in small/medium-sized biotechnology, diagnostics, medical device, and contract research organizations.

The AABC works to achieve their mission by working in areas of common interest in a pre-competitive space to advance both the field of Alzheimer’s research and the member company’s goals. The AABC member companies provide leadership and direction to the organizations areas of focus that include but are not limited to: Collaborations, Recognition & Visibility and Knowledge and Information Sharing.

News from AABC members and growth AD companies

ProMIS Neurosciences, Inc.

May 24, 2017- ProMIS Neurosciences, Inc., a biotech company focused on the discovery and development of precision treatments for neurodegenerative diseases, designated PMN350, a mAB that targets prion-like forms of amyloid-beta oligomers (AβO), its second lead product for Alzheimer’s disease. Read more.


June 6, 2017- ProMIS Neurosciences, Inc., appoints internationally renowned neurologist William C. Mobley, MD, PhD, to the Company’s Scientific Advisory Board. Read more.

May 31, 2017- ProMIS Neurosciences, Inc., identified a novel therapeutic epitope target on misfolded TDP43, a key player in ALS and Dementia. Read more.

ADM Diagnostics

ADM Diagnostics (ADMdx) will present “Relationships between tau burden measured using AV1451 PET, regional cerebral glucose metabolism, and cognitive status” at AAIC on July 18, 2017, poster P3-09. In this work, we evaluated relationships between amyloid status, tau stage, and the expression of AD-related hypometabolism as measured using our multivariate FDG PET AD Progression classifier, using the tau (AV-1451), amyloid (florbetapir), and FDG PET scans of more than 100 ADNI2 subjects. ADMdx is applying these methods to support clinical trials and research in Alzheimer’s disease.

In addition, Dawn Matthews, CEO, presented at the inaugural steering committee meeting of SAFTIE (Scanning to Assess for Traumatic Injury and Encephalopathy), an initiative established to advance the understanding and treatment of Traumatic Brain Injury and CTE. ADMdx is now applying advanced analysis methods to evaluate tau PET, FDDNP PET, and MRI image data acquired in sports professionals at risk for the development of Chronic Traumatic Encephalopathy (CTE).
The AABC Translation Animal Models group, chaired by Joseph Araujo, Intervivo Solutions, and facilitated by Jim Hendrix, Alzheimer’s Association, was formed and has held 2 meetings on March 27 and June 6. The group was formed with the goal to develop an assessment of the values of translational animal models in its ability to predict a clinical outcome in Alzheimer’s disease. The group is currently working on finalizing the mission statement, defining “translation” in the context of this effort, and creating a comprehensive animal models list that will be scored by the group.

### AABC Translational Animal Models Group Update

1. **Webinar: AABC Ask the Expert-Suzanne Hendrix-Pentara**

   **Date:** June 29, 2017, 11 am ET / 8 am PT

   Suzanne Hendrix has worked for the past 26 years as a biostatistician focusing on clinical trial research in many different indications. She has extensive experience designing clinical trials, writing statistical analysis plans, running analyses, writing statistical reports, interacting with the FDA and preparing manuscripts for publication. She is experienced at communicating statistical concepts in an understandable way, and has helped develop software for graphically understanding large complex datasets. For the past 14 years, she has specialized in statistical issues in Alzheimer’s disease such as identifying appropriate outcomes, addressing measurement issues, demonstrating disease modification and optimizing clinical trial design and analysis. She has been on multiple advisory boards and expert panels addressing current issues in Alzheimer’s disease, and has interacted with the division of Neurology products at the FDA and with the EMA through scientific advice regarding these issues. She is currently president and owner of Pentara Corporation (www.pentaracorp.com), a specialty CRO that provides data management and statistical consultation to the pharmaceutical industry, academic groups and non-profit groups, primarily supporting clinical trial design and optimization in Alzheimer’s disease. She has researched methods for discerning disease modification of treatments, and has proposed novel approaches to this problem. She is an active researcher in the Alzheimer’s disease field with over 100 publications and presentations.

   **Join by phone**
   
   Call-in toll-free number: 1-866-316-2054 (US)
   Call-in number: 1-763-391-6884 (US)
   Show global numbers
   Conference Code: 442 859 6748

   **Join WebEx meeting**
   
   Click here
   Meeting number: 743 899 110

2. **AABC Translational Animal Models Group Face-to-Face Lunch Meeting at Alzheimer’s Association International Conference (AAIC) 2017, London, United Kingdom**

   **Date:** Sunday, July 16, 12 -2 pm
   **Location:**
   - Hotel Novotel Excel London, Room: London II
   - 7 Western Gateway
   - Royal Victoria Dock
   - E16 1AA London – United Kingdom

3. **AABC Invited to the AAIC’s ISTAART Membership Reception**

   *(please note, to attend you must be a member of ISTAART)*

   **Date:** Monday, July 17, 6 -8 pm
   **Location:**
   - Re:mix Lounge
   - Aloft London Excel
   - One Eastern Gateway
   - Royal Victoria Dock
   - London, England, E16 1FR
4. AABC Invited to AAIC’s Reviewers Reception

Date: Tuesday, July 18, 7-9 pm  
Location: Crowne Plaza-Docklands, Docklands Bar & Grill  
          Royal Victoria Dock  
          Western Gateway  
          London, E16 1AL

* Can’t make it to AAIC? Don’t fret, another face-to-face meeting will be scheduled for the fall, event details will be provided at a later date*

5. Webinar: AABC Ask the Expert—Mark Amman—Catalyst Regulatory Services, LLC

Date: Tuesday, September 12, 11 am ET/ 8 am PT  
Topic: Regulatory issues in getting to IND and common mistakes to avoid

AABC Collaboration

Job postings

To post your job postings in future newsletters, please inform April Ross at aqross@alz.org

General postings to the AABC membership

To post any general postings in future newsletters, please inform April Ross at aqross@alz.org

Past Events

1. AABC/ISTAART Joint Webinar

On May 17, AABC and the International Society to Advance Alzheimer’s Research and Treatment (ISTAART) hosted a joint webinar titled Biotech Innovation in Fluid Biomarkers. The webinar focused on 4 companies’ diverse approaches of measuring biomarkers for Alzheimer’s disease by utilizing blood-based assays. To view the recording click here and enter your email address, the slides from the webinar are available on the AABC webpage.

2. AABC Ask The Expert

On April 4, AABC held its first Ask the Expert Webinar. The webinar featured David Feldman, Partner at Duane Morris LLP, he presented information on Regulation D, venture capital, Angels/friends and family, and Regulation A+ IPO financing options. The slides are available on the AABC webpage and you can click here for David’s bio.

Stay tuned for other events and updates.

Best wishes,

Jim Hendrix, Charles Stacey and Kira Sheinerman